Main Postoperative Complications After SARS-CoV-2 Infection


To explore the relationship between SARS-CoV-2 infection in different time before operation and postoperative main complications (mortality, main pulmonary and cardiovascular complications) 30 days after operation; To determine the best timing of surgery after SARS-CoV-2 infection.

Full Title of Study: “Main Postoperative Complications After SARS-CoV-2 Infection: A Prospective Cohort Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 1, 2024

Clinical Trial Outcome Measures

Primary Measures

  • All-cause mortality at 30 days after operation
    • Time Frame: 30 days after surgery
    • All-cause mortality at 30 days after operation

Secondary Measures

  • Main pulmonary complications at 30 days after operation
    • Time Frame: 30 days after surgery
    • a composite of postoperative pneumonia, acute respiratory distress syndrome (ARDS) and unexpected ventilation
  • Major Adverse Cardiovascular Events (MACE)
    • Time Frame: 30 days after surgery
    • a composite of myocardial infarction, new-onset heart failure or cardiogenic shock, deep vein thrombosis (DVT), pulmonary embolism (PE), and cerebrovascular accident (CVA)

Participating in This Clinical Trial

Inclusion Criteria

  • Ageā‰„18 years; – Patients undergoing any type of elective or confine surgery in operating room; – Informed consent. Exclusion Criteria:

  • Surgery under local anesthesia (without participation of anesthetist) – Surgery outside the operating room, such as gastrointestinal endoscopy, puncture biopsy, etc – Patients who cannot determine whether they have had SARS CoV-2 infection before surgery – Participating in conflicting clinical study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • RenJi Hospital
  • Collaborator
    • The First Affiliated Hospital of Anhui Medical University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Diansan Su, MD,PHD, Study Chair, Renji Hospital, Shanghai Jiaotong University, School of Medcine
  • Overall Contact(s)
    • Diansan Su, MD,PHD, +8618616514088,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.